Research programme: polyethylene glycol therapeutics - Medtronic Sofamor Danek

Drug Profile

Research programme: polyethylene glycol therapeutics - Medtronic Sofamor Danek

Latest Information Update: 05 Jul 2011

Price : $50

At a glance

  • Originator Medtronic Sofamor Danek
  • Class Magnesium compounds; Polyethylene glycols
  • Mechanism of Action Apoptosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Spinal cord injuries

Most Recent Events

  • 19 Nov 2008 Pharmacodynamics data from a preclinical trial in Spinal cord injuries presented at the 38th Annual Meeting for the Society of Neuroscience (SfN-2008)
  • 07 Nov 2007 Pharmacodynamics data from a preclinical study in Spinal cord injuries presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
  • 28 Dec 2004 The PEG technology has been licensed to Medtronic Sofamor Danek in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top